Allarity Therapeutics (ALLR) Stock Overview

A clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. More details

ALLR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings have grown 2.3% per year over the past 5 years

Risk Analysis

Earnings are forecast to decline by an average of 19.3% per year for the next 3 years

Makes less than USD$1m in revenue ($345K)

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the US market

+ 1 more risk

ALLR Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Allarity Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Allarity Therapeutics
Historical stock prices
Current Share Price	US$1.55
52 Week High	US$2.35
52 Week Low	US$0.77
Beta	0.52
1 Month Change	1.97%
3 Month Change	23.02%
1 Year Change	85.36%
3 Year Change	-99.90%
5 Year Change	n/a
Change since IPO	-99.90%

Recent updates

Seeking Alpha • Oct 11

Allarity Therapeutics GAAP EPS of -$0.72 misses by $0.46

Allarity Therapeutics press release (NASDAQ:ALLR): Q2 GAAP EPS of -$0.72 misses by $0.46. As of June 30, 2022, Allarity’s cash was $7.7 million, as compared to $19.6 million as of December 31, 2021 Shares +4.07%.

Seeking Alpha • Aug 23

Allarity Therapeutics GAAP EPS of -$0.52 misses by $0.07

Allarity Therapeutics press release (NASDAQ:ALLR): Q2 GAAP EPS of -$0.52 misses by $0.07. The company has incurred significant losses and has an accumulated deficit of $74.2M as of June 30, 2022. The company had no cash equivalents or restricted cash on June 30, 2022, and December 31, 2021. As of August 18, 2022, our cash is insufficient to fund our current operating plan and planned capital expenditures for the next 12 months.

Seeking Alpha • Jun 29

Allarity Therapeutics appoints interim CEO, CFO

The board of clinical-stage pharmaceutical company Allarity Therapeutics (NASDAQ:ALLR) appointed Chief Business Officer James Cullem interim CEO and Director of Financial Reporting Joan Brown interim CFO, with immediate effect. Former CEO Steve Carchedi and CFO Jens Knudsen have resigned to pursue other opportunities. A permanent CEO and CFO could be named in H1 2023. Source: Press Release

Shareholder Returns

	ALLR	US Biotechs	US Market
7D	-8.8%	-0.9%	-2.4%
1Y	85.4%	25.7%	21.5%

Return vs Industry: ALLR exceeded the US Biotechs industry which returned 23.6% over the past year.

Return vs Market: ALLR exceeded the US Market which returned 20.6% over the past year.

Price Volatility

Is ALLR's price volatile compared to industry and market?
ALLR volatility
ALLR Average Weekly Movement	11.3%
Biotechs Industry Average Movement	10.6%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ALLR's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ALLR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
n/a	8	Thomas Jensen	www.allarity.com

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer.

Allarity Therapeutics, Inc. Fundamentals Summary

How do Allarity Therapeutics's earnings and revenue compare to its market cap?
ALLR fundamental statistics
Market cap	US$23.04m
Earnings (TTM)	-US$11.25m
Revenue (TTM)	US$345.00k

69.5x

P/S Ratio

-2.1x

P/E Ratio

Is ALLR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALLR income statement (TTM)
Revenue	US$345.00k
Cost of Revenue	US$0
Gross Profit	US$345.00k
Other Expenses	US$11.59m
Earnings	-US$11.25m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-0.73
Gross Margin	100.00%
Net Profit Margin	-3,260.58%
Debt/Equity Ratio	310.6%

How did ALLR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/11 16:21
End of Day Share Price	2026/06/11 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Allarity Therapeutics, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Edward Woo	Ascendiant Capital Markets LLC
Nathaniel Calloway	Edison Investment Research
Aydin Huseynov	Ladenburg Thalmann & Company

Allarity Therapeutics (ALLR) Stock Overview

Rewards

Risk Analysis

Allarity Therapeutics, Inc. Competitors

AIxCrypto Holdings

RenovoRx

Theriva Biologics

Forum Markets

Price History & Performance

Recent News & Updates

Price target increased by 7.9% to US$10.25

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics, Inc., Annual General Meeting, Jun 26, 2026

Allarity Therapeutics, Inc. announced that it has received $20.93 million in funding

Allarity Therapeutics, Inc. Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

Recent updates

Price target increased by 7.9% to US$10.25

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics, Inc., Annual General Meeting, Jun 26, 2026

Allarity Therapeutics, Inc. announced that it has received $20.93 million in funding

Allarity Therapeutics, Inc. Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

Allarity Therapeutics, Inc. Announces Collaborative Phase 2 Trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer Is Now Open for Enrollment

New major risk - Revenue and earnings growth

Allarity Therapeutics, Inc. Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Now Surpasses 25 Months

Allarity Therapeutics, Inc. announced that it expects to receive $10 million in funding

Allarity Therapeutics, Inc. Receives FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

Allarity Therapeutics, Inc. announced delayed 10-Q filing

Allarity Therapeutics, Inc. Announces Chief Financial Officer Changes

Allarity Therapeutics, Inc. Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic

Allarity Therapeutics, Inc. Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

High number of new and inexperienced directors

Allarity Therapeutics, Inc Announces Changes to Board of Directors

Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer

Allarity Therapeutics, Inc., Annual General Meeting, Jun 13, 2025

Allarity Therapeutics, Inc. Announces Thomas H. Jensen Moves from Class I Director to Class III Director

Allarity Therapeutics, Inc. Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients At the 2025 Annual Meeting for the Society of Gynecologic Oncology

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Allarity Therapeutics, Inc. Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Allarity Therapeutics, Inc. (NasdaqCM:ALLR) announces an Equity Buyback for $5 million worth of its shares.

Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit

Allarity Therapeutics, Inc. to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward Fda Approval in Advanced Ovarian Cancer Patients

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Allarity Therapeutics, Inc. Announces Management Appointments

Holzer & Holzer, LLC Announces Class Action Lawsuit on Behalf of Allarity Therapeutics, Inc

Allarity Therapeutics, Inc. Appoints Alex Epshinsky as Chief Financial Officer

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)

Allarity Therapeutics Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance

Allarity Therapeutics, Inc.' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer

Allarity Therapeutics, Inc., Annual General Meeting, Jul 26, 2024

Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial

Allarity Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10 million.

Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

Allarity Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $0.947 million.

Allarity Therapeutics, Inc. announced that it has received $0.6 million in funding

Allarity Therapeutics, Inc. announced that it has received $0.8 million in funding from 3i, LP

Allarity Therapeutics, Inc. Announces Resignation of James G. Cullem as Member of the Board

Allarity Therapeutics Announces Executive Changes

Allarity Therapeutics, Inc. Announces Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic

Allarity Therapeutics, Inc. Receives A Letter from Nasdaq Listing Qualifications Staff

Allarity Therapeutics Receives Notification from the Nasdaq Listing Qualifications Staff Regarding Non-Compliance with Listing Rule 5550(a)(2)

Allarity Therapeutics Announces Positive Early Data from an Ongoing Clinical Trial, and External Partnering for Its DRP Technology

Allarity Therapeutics, Inc. Announces the Publication of its Clinical Validation of a Novel Drug-Specific DRP-Companion Diagnostic (CDx) for Dovitinib in the Peer-Reviewed Journal PLOS ONE

Allarity Therapeutics, Inc. Announces Board Changes

Allarity Therapeutics, Inc. and Detsamma Investments Pty. Ltd. Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics

Allarity Therapeutics, Inc. Provides Nasdaq Compliance Update

Allarity Therapeutics, Inc. Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

Allarity Therapeutics, Inc. Announces Initial Results from Its European Phase 2 Clinical Trial Evaluating the Efficacy of Ixempra®? in Metastatic Breast Cancer Patients

Allarity Therapeutics, Inc. announced that it expects to receive $0.35 million in funding from 3i, LP

Allarity Therapeutics Announces Reverse Stock Split of Common Stock to Bring it into Compliance with Nasdaq’s Listing Requirement Regarding Minimum Share Price

Allarity Therapeutics, Inc. Announces Results of Prospective Phase 2 Clinical Study

Allarity Therapeutics Announces Update on Delisting from The Nasdaq Stock Market

Allarity Therapeutics, Inc. Announces Board Changes